Biodesix Inc (BDSX) stock
Close on Nov 12, 2026Market cap $103.30MP/E –Yield –
Biodesix Inc grew revenue 31.2% to $105.21M over the twelve months to Sep 30, 2026. Free cash flow was -$19.07M. At the latest close the market valued the company at $103.30M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $103.30M
- P/E ratio
- –
- Price to sales
- 0.98
- Price to book
- 11.91
- Dividend yield
- –
- Free cash flow yield
- -18.47%
Fundamentals
- Revenue
- $105.21M
- Net income
- -$27.08M
- EPS, diluted
- -$2.76
- Free cash flow
- -$19.07M
- Book value per share
- $0.81
- Diluted shares
- 11M
Trading
- Next earnings
- Feb 25, 2027 (estimated, after the close)
- Previous close
- $10.12
- Open
- $10.17
- Day's range
- $9.70 – $10.87
- Volume
- 297,106
- Average volume (20 days)
- 266,933
- Beta (5 years)
- 0.73
- 52-week range
- $5.26 – $31.97
- RSI (14 days)
- 24.2
- Volatility (1 year)
- 121.6%
- Relative volume
- 4.39×
- WACC
- 9.5%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | BDSX | S&P 500 | Difference | BDSX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -61.9% | -2.7% | −59.2 pts | ||
| 3 months | -59.6% | -1.7% | −57.8 pts | ||
| Year to date | +44.0% | +11.9% | +32.1 pts | ||
| 1 year | +23.1% | +12.0% | +11.2 pts | ||
| 3 years | -59.2% | +78.2% | −137.4 pts | -25.8% | +21.2% |
| 5 years | -93.7% | +73.2% | −167.0 pts | -42.5% | +11.6% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Biodesix filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Biodesix
Services-Medical Laboratories
Biodesix, Inc. is a healthcare diagnostics company that develops and provides personalized diagnostic tests, primarily for patients with lung disease. The company operates through two main business segments: Lung Diagnostic Testing and Development Services. In its diagnostic testing segment, the company offers five blood-based tests, including two assays that evaluate cancer risk in lung nodules and three assays that guide treatment decisions following a cancer diagnosis. These clinical tests serve healthcare providers, medical clinics, and hospital systems. In its development services segment, the company provides diagnostic testing, research, and consulting services to biopharmaceutical, life sciences, and diagnostic companies.
Company profile, executives and historyBiodesix stock: common questions
What is Biodesix's stock price?
BDSX closed at $9.79 on Nov 12, 2026, down 3.26% on the day. Over the past 52 weeks it traded between $5.26 and $31.97.
What is Biodesix's market cap?
Biodesix was worth $103.30M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is BDSX's P/E ratio?
Biodesix lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.76), so it has no meaningful P/E ratio.
How much revenue does Biodesix make?
Biodesix reported revenue of $105.21M for the twelve months to Sep 30, 2026, up 31.2% from a year earlier.
Does Biodesix pay a dividend?
No. Biodesix has not paid a cash dividend over the last twelve months.
When does Biodesix report earnings next?
Biodesix is expected to report Q4 FY2026 results on Feb 25, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has BDSX stock performed over the past year?
Including dividends, BDSX returned +23.1% over the past year, against +12.0% for the S&P 500.
Who are Biodesix's competitors?
Companies most similar to Biodesix by business, industry and size include MDXH, PSNL, CSTL, XGN, GRAL.
See a number that looks wrong?